Interaction of silymarin components and their sulfate metabolites with human serum albumin and cytochrome P450 (2C9, 2C19, 2D6, and 3A4) enzymes - 16/04/21
páginas | 10 |
Iconografías | 8 |
Vídeos | 0 |
Otros | 0 |
Abstract |
Silymarin is a mixture of flavonolignans isolated from the fruit of milk thistle (Silybum marianum (L.) Gaertner). Milk thistle extract is the active ingredient of several medications and dietary supplements to treat liver injury/diseases. After the oral administration, flavonolignans are extensively biotransformed, resulting in the formation of sulfate and/or glucuronide metabolites. Previous studies demonstrated that silymarin components form stable complexes with serum albumin and can inhibit certain cytochrome P450 (CYP) enzymes. Nevertheless, in most of these investigations, silybin was tested; while no or only limited information is available regarding other silymarin components and metabolites. In this study, the interactions of five silymarin components (silybin A, silybin B, isosilybin A, silychristin, and 2,3-dehydrosilychristin) and their sulfate metabolites were examined with human serum albumin and CYP (2C9, 2C19, 2D6, and 3A4) enzymes. Our results demonstrate that each compound tested forms stable complexes with albumin, and certain silymarin components/metabolites can inhibit CYP enzymes. Most of the sulfate conjugates were less potent inhibitors of CYP enzymes, but 2,3-dehydrosilychristin-19-O-sulfate showed the strongest inhibitory effect on CYP3A4. Based on these observations, the simultaneous administration of high dose silymarin with medications should be carefully considered, because milk thistle flavonolignans and/or their sulfate metabolites may interfere with drug therapy.
El texto completo de este artículo está disponible en PDF.Graphical Abstract |
Highlights |
• | Interactions of silymarin components and their sulfate conjugates were examined. |
• | Flavonolignans formed stable complexes with serum albumin. |
• | Most of the compounds tested considerably displaced warfarin from albumin. |
• | Certain silymarin components significantly inhibited CYP2C9, 2C19, and/or 3A4. |
• | 2,3-dehydrosilychristin-19-O-sulfate was the strongest inhibitor of CYP3A4. |
Keywords : Silymarin, Sulfate conjugates, Human serum albumin, Cytochrome P450, Pharmacokinetic interaction, Herb-drug interaction
Esquema
Vol 138
Artículo 111459- juin 2021 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?